Chronic idiopathic urticaria is #urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, #omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes. Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chronic idiopathic urticaria, but also for moderate to severe asthma and nasal polyps. In recent years, practitioners have been expanding the number of off-label uses of this medication to treat multiple dermatologic conditions given its efficacious mechanism of action of inhibiting IgE-mediated inflammation. @GWDERMRES Dr. Alexis Carrington @dralexiscarrington continues our Therapeutic Cheat Sheet series with a look at omalizumab and its increased off-label use for several dermatologic conditions, including chronic idiopathic urticaria and bullous pemphigoid. Follow the link in our bio to download today's cheat sheet: https://nextstepsinderm.com/derm-topics/omalizumab-therapeutic-cheat-sheet/ #dermatologist #boardcertifieddermatogist #dermatologyresident #dermatologylife #medicaldermatology #derms #dermresidents #dermleader #futurederm #dermlife #nextstepsinderm #dermatologyfellows #skin #skincare #healthyskin #health #medicine #dermatology